The Conserve® Plus (Wright Medical Technology Inc., Arlington, TN) was introduced clinically in the United States in 1996. A study of the serum cobalt and chromium ion levels was started in 2000 in our center to monitor the metal ion levels over time as part of an FDA clinical trial. Thirteen male and five female patients received this resurfacing for idiopathic osteoarthritis (14), post-traumatic degenerative changes (3) or developmental dysplasia (1). Fourteen received a unilateral implant but four subsequently received a contralateral device from 52 to 86 months post-op. Four patients had bilateral resurfacings done in a one-stage procedure. All surgeries were performed by the senior author. None of these patients had known exposure to cobalt or chromium, kidney disease or other metal implants elsewhere in their bodies. Each prospectively provided blood samples and then yearly thereafter to measure cobalt and chromium levels for up to 11 years. Metal levels were measured using atomic absorption spectrophotometry and inductively coupled plasma mass spectrometry by a specialized trace element analysis laboratory. Acetabular component position was evaluated using Einzel-Bild-Röentgen-Analysis (EBRA) software. Contact patch to rim (CPR) distance was computed as described by Langton et al JBJS Br 91: 2009. A mixed model linear regression analysis was performed to evaluate long term trends, and multivariate analysis was performed to examine effects of implant and patient covariates on the metal ion levels. One bilateral patient underwent revision for femoral loosening, all other patients were clinically well-functioning at the time of last follow-up (ave 89 mos). The median pre-operative Co was below the detection limit (d.l) of 0.3μg/L and the median pre-operative Cr was 0.069μg/L (d.l. 03μg/L). Metal levels increased within the first year then decreased and stabilized (fig 1). For unilaterals over all time intervals, the median Co was 1.06 μg/L, while the median Cr was 1.58 μg/L. For bilaterals, the mean post-operative Co was 2.80 μg/L, while the mean Cr was 5.80 μg/L. Generally, Cr levels were higher at all time points than Co. Bilateral patients had Co values 1.96 times greater on average than the unilateral patients (p<0.001). None of the possible covariates studied (femoral size, cup abduction angle, cup anteversion, CPR distance, activity, BMI and testing method) were related to the assay values. The results of this study have shown that serum metal levels in well functioning implants can be low and do not increase over time. These are among the lowest levels reported for resurfacing devices and comparable to levels reported for well functioning small diameter metal-on-metal total hips. The study is limited due to the relatively small sample size and limited range of values for the covariates studied. However, it included patients who were active, female or bilateral and we collected ion levels up to 11 years. We now recommend that patients who have well-oriented Conserve Plus components with stable radiographic interfaces and no incidences of unexplained pain or hip noises be scheduled for follow-up every 2–3 years, rather than annually.
Ion levels in the serum and urine of patients with metal-on-metal hip resurfacing implants can provide a means to monitor bearing wear. This presentation will discuss the current results, now out to 5 years for the Conserve Plus resurfacing. In particular, the effect of bilateral implantation on ion levels was examined Forty-eight patients were studied. Forty-three of these cases were initially implanted with a unilateral resurfacing. Nine of these cases subsequently were implanted with a resurfacing implant on the contra-lateral side 4 to 48 months following the first implantation (staged implantations). Five cases had bilateral resurfacings done simultaneously. All surgeries were done in one institution by a single surgeon. Serum and urine samples were collected pre-operatively, and at 4 months, 12 months and annually thereafter. The samples were analysed for cobalt and chromium using atomic absorption spectrometry with a detection limit of 0.3 to 0.03ng/ml respectively. The data were compared between the groups and also correlated with UCLA activity scores, cup angle, BMI and component size. All patients showed a rise in ions following implantation. The simultaneous bilateral levels were higher at all time periods compared with the staged bilaterals monitored at the same time point for the second hip, for example cobalt serum at 12 month uni = 2.24, simultaneous bilat = 2.53, staged bilat = 2.05ng/ml, and at 4 years uni = 1.20, simultaneous bilat = 2.93, staged bilat = 2.27ng/ml. There was no correlation between ion levels and UCLA activity score, gender, component size or cup angle (but only 4 hips had cups >
55 degrees). Bilateral metal-on-metal hip resurfacings performed simultaneously resulted in higher levels of metal ions, particularly chromium, compared to staged implantations monitored at the same time periods. With the exception of a small number of outliers, the levels in this group of hip resurfacings were within the range of metal levels reported for other metal-on-metal total hips.